Quick summary
VK2735 is a novel dual GLP-1/GIP receptor agonist developed by Viking Therapeutics for obesity. Phase 2 VENTURE trial results showed up to 14.7% weight loss at 13 weeks, with both subcutaneous and oral formulations advancing to Phase 3.
Overview
VK2735 is a novel synthetic dual agonist of the GLP-1 and GIP receptors developed by Viking Therapeutics for treatment of obesity and metabolic disorders. Available in both subcutaneous and oral formulations, it is structurally distinct from tirzepatide while targeting the same dual receptor pathway. Phase 2 VENTURE trial results published in the journal Obesity (January 2026) demonstrated up to 14.7% weight loss at 13 weeks, with Phase 3 trials (VANQUISH-1 and VANQUISH-2) currently enrolling.
Mechanism of action
VK2735 is a co-agonist designed to simultaneously activate two incretin receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). GLP-1R activation drives glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite suppression via hypothalamic and brainstem pathways. GIPR co-activation amplifies the insulinotropic response and has been shown in preclinical models to enhance adipose tissue fatty acid oxidation, reduce fat mass independently of caloric restriction, and modulate central reward pathways that drive hedonic eating. The dual receptor engagement produces synergistic weight loss beyond what GLP-1R agonism alone achieves, consistent with observations from tirzepatide. The oral formulation uses a proprietary delivery technology to overcome GLP-1 peptide degradation in the GI tract.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| obesity treatment (subcutaneous formulation — clinical trial dosing) | subcutaneous | 0.5–2.4 mg | once weekly | Phase 2 VENTURE trial used escalating doses from 0.5 mg to 2.4 mg/week over 13 weeks. Dose titration schedule mirrors tirzepatide pattern. Not available outside clinical trials. |
| obesity treatment (oral formulation — clinical trial dosing) | oral | 25–100 mg | once daily | Oral Phase 2 trial used daily dosing with 4-week titration steps. Oral bioavailability requires higher nominal dose vs. subcutaneous. Investigational only. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
The Phase 2 VENTURE trial (subcutaneous formulation, 13 weeks, n=176 adults with obesity) demonstrated mean weight loss of 13.1% at 2.4 mg/week and up to 14.7% at higher doses versus 2.2% placebo. All doses above 15 mg showed statistically significant weight loss vs. placebo by week 1. The oral Phase 2 VENTURE-Oral trial showed up to 12.2% mean weight loss at 13 weeks, with results published January 2026. Phase 3 VANQUISH program initiated 2025; pivotal outcomes pending.[1]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with VK2735 for synergistic effects.
Legal status
Investigational compound as of 2026. Not FDA-approved. Being evaluated under IND in Phase 3 clinical trials (VANQUISH-1, VANQUISH-2). Not available by prescription; research chemical suppliers may offer non-GMP versions of uncertain purity. Viking Therapeutics retains exclusive development rights. No compounding pharmacy pathway as of 2026.
Sourcing & access
Research compound
VK2735 is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
VK2735 is a synthetic dual agonist of the GLP-1 and GIP receptors developed by Viking Therapeutics. Available in both subcutaneous and oral formulations, it targets the same dual receptor pathway as tirzepatide while being structurally distinct.
VK2735 simultaneously activates GLP-1 and GIP receptors. GLP-1R activation drives appetite suppression and slowed gastric emptying, while GIPR co-activation enhances insulin response, promotes fat oxidation, and modulates reward pathways. The dual mechanism produces synergistic weight loss.
Phase 2 side effects include nausea (most common, dose-dependent), vomiting, diarrhea, decreased appetite, fatigue, and headache. The safety profile is consistent with other GLP-1 class agents. VK2735 is investigational and not yet FDA-approved.
The Phase 2 VENTURE trial showed mean weight loss of 13.1% at 2.4 mg/week and up to 14.7% at higher doses versus 2.2% for placebo over 13 weeks. The oral formulation showed up to 12.2% weight loss at 13 weeks.